文献速递类风湿关节炎

Olokizumab联合甲氨蝶呤治疗甲氨蝶呤控制不佳的类风湿关节炎:随机对照III期研究

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
PubMed 文献 · Ann Rheum Dis · 2021-08-03

这项24周多中心、安慰剂对照、双盲III期研究纳入428例甲氨蝶呤控制不佳的活动性类风湿关节炎患者,随机接受Olokizumab 64 mg每2周或每4周皮下注射或安慰剂联合甲氨蝶呤。第12周ACR20应答率在OKZ每2周组为63.6%、每4周组为70.4%,均显著高于安慰剂组的25.9%(p<0.0001)。所有次要疗效终点在OKZ组与安慰剂组间均有显著差异。

要点

  • OKZ 64 mg每2周或每4周联合MTX均显著提高第12周ACR20应答率
  • 所有次要疗效终点在OKZ组与安慰剂组间均有显著差异
  • OKZ组治疗中出现严重不良事件的患者数多于安慰剂组,感染最常见

核心结论

  • OKZ联合MTX可显著改善MTX控制不佳的活动性RA患者的体征、症状和躯体功能。
  • 两种给药方案(每2周与每4周)之间未见明显差异。
  • 安全性与该类药物的预期一致,免疫原性低。

研究设计与样本

  • 24周多中心、安慰剂对照、双盲III期研究。
  • 患者按1:1:1随机接受皮下OKZ 64 mg每2周、OKZ 64 mg每4周或安慰剂,均联合MTX。
  • 共428例患者被随机分组。
  • 主要疗效终点为第12周达到ACR20应答的患者比例。
  • 次要疗效终点包括第12周DAS28-CRP<3.2、HAQ-DI,以及第24周ACR50和CDAI≤2.8。

主要发现

  • 第12周ACR20应答率:OKZ每2周组63.6%,OKZ每4周组70.4%,安慰剂组25.9%(两项比较均p<0.0001)。
  • 所有次要疗效终点在OKZ治疗组与安慰剂组之间均有显著差异。
  • OKZ组报告治疗中出现严重不良事件(TESAEs)的患者数多于安慰剂组。
  • 感染是最常见的TESAEs。
  • 未出现中和性抗药抗体。

关键数值与推荐

  • 主要终点为第12周ACR20应答率。
  • 次要终点包括第12周DAS28-CRP<3.2、HAQ-DI,第24周ACR50和CDAI≤2.8。
  • OKZ剂量为64 mg皮下注射,每2周或每4周一次。
  • 试验注册号NCT02760368。

临床怎么用

  • 对于MTX控制不佳的活动性RA患者,OKZ联合MTX可考虑作为改善病情的治疗选择。
  • 每2周与每4周给药方案疗效未见明显差异。
  • 使用OKZ时需关注严重不良事件,尤其是感染。
  • OKZ免疫原性低,未出现中和性抗药抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX). METHODS: In this 24-week multicentre, placebo-controlled, double-blind study, patients were randomised 1:1:1 to receive subcutaneously administered OKZ 64 mg once every 2 weeks, OKZ 64 mg once every 4 weeks, or placebo plus MTX. The primary efficacy endpoint was the proportion of patients achieving an American College of Rheumatology 20% (ACR20) response at week 12. The secondary efficacy endpoints included percentage of subjects achieving Disease Activity Score 28-joint count based on C reactive protein <3.2, Health Assessment Questionnaire Disability Index at week 12, ACR50 response and Clinical Disease Activity Index ≤2.8 at week 24. Safety and immunogenicity were assessed throughout the study. RESULTS: A total of 428 patients were randomised. ACR20 responses were more frequent with OKZ every 2 weeks (63.6%) and OKZ every 4 weeks (70.4%) than placebo (25.9%) (p<0.0001 for both comparisons). There were significant differences in all secondary efficacy endpoints between OKZ-treated arms and placebo. Treatment-emergent serious adverse events (TESAEs) were reported by more patients in the OKZ groups compared with placebo. Infections were the most common TESAEs. No subjects developed neutralising antidrug antibodies. CONCLUSIONS: Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. Safety was as expected for this class of agents. Low immunogenicity was observed. Trial registration number NCT02760368.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2021. PMID: 34344706. doi:10.1136/annrheumdis-2021-219876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。